

US Family Health Plan
 Prior Authorization Request Form for
 Ophthalmic Anti-Inflammatory Immunomodulatory Agents:
 Lifitegrast Ophthalmic Solution (**Xiidra**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be **faxed to 617-562-5296**

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? **Call 1-877-880-7007**

Prior authorization for initial therapy and renewal therapy will approve for 1 time only. Continuous therapy within 120 days will not require an additional prior authorization, however, if drug therapy (patient has not filled the Rx) has a break of greater than 120 days then an additional prior authorization is required.

Step 1 Please complete patient and physician information (please print):

Patient Name: _____ Address: _____ Sponsor ID #: _____ Date of Birth: _____	Physician Name: _____ Address: _____ Phone #: _____ Secure Fax #: _____
--	--

Step 2 Please complete the clinical assessment:

1. Is this drug being prescribed by an ophthalmologist or optometrist?	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No STOP Coverage not approved
2. Is the patient greater than or equal to 18 years of age?	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No STOP Coverage not approved
3. Will Xiidra be used in combination with Restasis?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 4
4. Is Xiidra being prescribed for LASIK associated dry eyes?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 5
5. Is the request for renewal of therapy?	<input type="checkbox"/> Yes Proceed to question 11	<input type="checkbox"/> No Proceed to question 6
6. Does the patient have a diagnosis of Moderate to Severe Dry Eye Disease?	<input type="checkbox"/> Yes Proceed to question 7	<input type="checkbox"/> No STOP Coverage not approved
7. Has the patient had positive symptomology screening for moderate to severe dry eye disease from an appropriate measure?	<input type="checkbox"/> Yes Proceed to question 8	<input type="checkbox"/> No STOP Coverage not approved

Prior Authorization Request Form for
Ophthalmic Anti-Inflammatory Immunomodulatory Agents:
Lifitegrast Ophthalmic Solution (Xiidra)

<p>8. Has the patient had at least one positive diagnostic test (e.g. Tear Film Breakup Time, Osmolarity, Ocular Surface Staining, Schirmer Tear Test)?</p>	<p><input type="checkbox"/> Yes Proceed to question 9</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>9. Has the patient tried and failed at least 1 month of one ocular lubricant used at optimal dosing and frequency (e.g. carboxymethylcellulose [Refresh, Celluvisc, Thera Tears, Genteal, etc], polyvinyl alcohol [Liquitears, Refresh Classic, etc], or wetting agents [Systeme, Lacrilube)?</p>	<p><input type="checkbox"/> Yes Proceed to question 10</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>10. Has the patient tried and failed at least 1 month of a different ocular lubricant that is non-preserved at optimal dosing and frequency (e.g. carboxymethylcellulose, polyvinyl alcohol, etc.)?</p>	<p><input type="checkbox"/> Yes Sign and date below</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>11. Does the patient have documented improvement in ocular discomfort?</p>	<p><input type="checkbox"/> Yes Proceed to question 12</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>12. Does the patient have documented improvement in signs of dry eye disease?</p>	<p><input type="checkbox"/> Yes Sign and date below</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>

Step I certify the above is true to the best of my knowledge. Please sign and date:

3

Prescriber Signature

Date

[25 July 2018]